EGFR and lung cancer: Researchers found that the action of aumolertinib was optimized by the use of a cyclopropyl group to replace a methyl group on the indole ring of osimertinib, thus allowing potentially greater selectivity against EGFR T790M to mediate the progression and metastasis of lung cancer, thereby reducing damage to lung tissue to some degree [32, 33].